RMD:NYE-ResMed Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 248.93

Change

-1.78 (-0.71)%

Market Cap

USD 8.15B

Volume

1.34M

Analyst Target

USD 184.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-2.77 (-1.18%)

USD 67.65B
ALC Alcon AG

-1.46 (-1.48%)

USD 48.64B
BAX Baxter International Inc

-0.45 (-1.12%)

USD 20.54B
AVTR Avantor Inc

-0.33 (-1.21%)

USD 18.49B
TFX Teleflex Incorporated

-4.61 (-1.87%)

USD 11.63B
ATR AptarGroup Inc

+0.04 (+0.03%)

USD 10.16B
BLCO Bausch + Lomb Corp

+0.76 (+4.27%)

USD 6.26B
STVN Stevanato Group SpA

-0.21 (-1.09%)

USD 5.62B
WRBY Warby Parker Inc

-0.12 (-0.80%)

USD 1.57B
INFU InfuSystems Holdings Inc

-0.09 (-1.38%)

USD 0.14B

ETFs Containing RMD

EKG First Trust Nasdaq Lux Di.. 10.77 % 0.00 %

-0.11 (1.38%)

USD 2.48M
EDOC:AU BetaShares Digital Health.. 9.23 % 0.00 %

-0.01 (1.38%)

N/A
FDHT 5.30 % 0.00 %

N/A

N/A
EDOG:LSE Global X Telemedicine & D.. 5.27 % 0.00 %

+0.14 (+1.38%)

USD 0.22M
EDOC:LSE Global X Telemedicine & D.. 5.17 % 0.00 %

+0.16 (+1.38%)

USD 3.75M
EDOC Global X Telemedicine & D.. 5.15 % 0.00 %

+0.10 (+1.38%)

USD 0.04B
FDOC:LSE Fidelity Digital Health U.. 5.14 % 0.00 %

+0.05 (+1.38%)

USD 3.04M
DDOC:XETRA Global X Telemedicine & D.. 5.03 % 0.00 %

+0.14 (+1.38%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 5.03 % 0.00 %

-0.02 (1.38%)

USD 4.62M
MCSE Martin Currie Sustainable.. 4.88 % 0.00 %

-0.04 (1.38%)

N/A
EDOC:SW Global X Telemedicine & D.. 4.25 % 0.00 %

+0.15 (+1.38%)

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.19 % 0.00 %

+0.05 (+1.38%)

N/A
ENTR ERShares Entrepreneurs ET.. 3.73 % 0.49 %

N/A

USD 0.09B
FAIR:AU BetaShares Australian Sus.. 3.52 % 0.00 %

+0.11 (+1.38%)

USD 1.50B
EX20:AU BetaShares Australian Ex-.. 2.55 % 0.00 %

+0.06 (+1.38%)

USD 0.27B
HLTH:AU VanEck Global Healthcare .. 2.51 % 0.00 %

+0.01 (+1.38%)

USD 0.06B
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.36 % 0.00 %

+0.02 (+1.38%)

N/A
RISN Inspire Tactical Balanced.. 1.23 % 0.00 %

+0.04 (+1.38%)

USD 0.09B
KRMA Global X Conscious Compan.. 0.56 % 0.43 %

-0.01 (1.38%)

USD 0.63B
BLES Inspire Global Hope ETF 0.31 % 0.62 %

+0.05 (+1.38%)

USD 0.11B
JKH 0.00 % 0.30 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

-0.33 (1.38%)

USD 0.22B
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

+0.15 (+1.38%)

N/A
VCAV:XETRA VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 0.01B
CVGB:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 2.24M
CAVE:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

N/A
CAVE:SW VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 44.71% 100% F 96% N/A
Dividend Return 1.17% 67% D+ 28% F
Total Return 45.88% 100% F 95% A
Trailing 12 Months  
Capital Gain 71.22% 100% F 96% N/A
Dividend Return 1.72% 67% D+ 26% F
Total Return 72.93% 100% F 96% N/A
Trailing 5 Years  
Capital Gain 88.31% 87% B+ 85% B
Dividend Return 6.92% 86% B+ 21% F
Total Return 95.23% 87% B+ 84% B
Average Annual (5 Year Horizon)  
Capital Gain 5.72% 47% F 58% F
Dividend Return 6.56% 42% F 53% F
Total Return 0.84% 44% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 27.29% 68% D+ 38% F
Risk Adjusted Return 24.02% 63% D 43% F
Market Capitalization 8.15B 86% B+ 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.70 80% 20%
Price/Book Ratio 7.40 14% 12%
Price / Cash Flow Ratio 25.68 29% 11%
Price/Free Cash Flow Ratio 23.98 8% 12%
Management Effectiveness  
Return on Equity 22.70% 100% 87%
Return on Invested Capital 20.47% 93% 89%
Return on Assets 12.70% 100% 96%
Debt to Equity Ratio 14.34% 91% 84%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.